CJC-1295 / Ipamorelin
Also known as CJC-1295 + Ipamorelin, GHRH analog / secretagogue blend
CJC-1295 / ipamorelin is the canonical research pairing of a GHRH analog with a ghrelin-receptor secretagogue. A profile of why two mechanisms are studied as one combination.
This entry is different from the others in the cluster because it is not one compound — it is a combination, and the combination itself is the subject. CJC-1295 and ipamorelin are the two most-paired molecules in growth-hormone-axis research, and understanding why means understanding that they do not do the same thing.
The page stays descriptive: what each half contributes to the pairing, why researchers combine two receptor mechanisms, and the contexts the pairing appears in. No dosing, no promised outcomes.
Not a single molecule but a studied pairing of two: a modified GRF(1-29) GHRH analog (CJC-1295, most often the no-DAC form) and ipamorelin, a selective ghrelin-receptor agonist. The rationale is mechanistic — the two components act on two different receptors in the same pathway.
Two receptors, one axis
The pituitary receives two natural signals about growth-hormone release: growth-hormone-releasing hormone (GHRH) and ghrelin, each acting through its own receptor. CJC-1295 is an analog of the first; ipamorelin is a mimetic of the second. Combining them is a way to engage both inputs at once rather than either alone — which is exactly why the pairing is studied instead of the single agents.
This is the practical reason the whole product cluster is organized around the GHRH-analog versus secretagogue distinction. The combination product is where that distinction pays off.
What each half brings
The CJC-1295 side supplies the GHRH-analog signal, most commonly as the short-acting no-DAC (Mod GRF 1-29) form so that its action stays pulsatile rather than sustained. The ipamorelin side supplies a selective ghrelin-receptor agonist — chosen over the older GHRPs for its narrower profile.
Studied together, the two are frequently described as complementary: the pairing is investigated on the basis that co-activating distinct receptors is mechanistically different from activating one. That is a description of research design, not a claim about results.
These are research areas the compound is associated with in the literature — not medical claims or intended uses.
Handling & storage
Supplied lyophilized, often as separately characterized components. Stored sealed and cold; reconstituted with bacteriostatic water only as a protocol requires, then refrigerated. Because it is a pairing, verify each component against its own certificate.
Verify a certificate by lot →Common questions
No. It is a research pairing of two distinct molecules — a GHRH analog (CJC-1295) and a ghrelin-receptor secretagogue (ipamorelin) — studied together.
They act on two different receptors that both feed the growth-hormone axis. The pairing is investigated to study co-activation of both inputs rather than either alone.
Most often the no-DAC (Mod GRF 1-29) form, so the GHRH-analog signal stays short-acting alongside ipamorelin. The DAC form is also studied but behaves as a long-acting analog.
This monograph is a research-use reference. It describes composition and the contexts in which the compound has been studied — it is not medical advice, a description of effects, or a recommendation for use. Sold strictly for laboratory and research use; not for human or animal consumption.